Praluent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 6.) Forty Seven Inc (NASDAQ: FTSV) Masimo Corporation (NASDAQ: MASI) Seattle Genetics, Inc. (NASDAQ: SGEN) Vertex Pharmaceuticals Incorporated (...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were rebounding Tuesday as investors digested French pharma giant and collaboration partner Sanofi SA's (NASDAQ: SNY) potential liquidation of its Regeneron stake — and the restructuring of a collaboration agreement between the...

Biotech stocks came under selling pressure in March, but much of the FDA decisions of the month produced positive results. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is...

Biotech stocks had a fairly decent run up in July after a nearly flat performance in June. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) is up about 5 percent. As the earnings season kicks into high gear and amid several other catalysts, August is likely to be an action-packed...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)’s promising Praluent trial outcomes — and an effective marketing strategy to expand access to the drug — could give the company a strong competitive standing in the cardiovascular drug market, according to Bank of America Merrill Lynch...

Amgen, Inc. (NASDAQ: AMGN) lost a major patent case Thursday when a U.S. appeals court reversed a ban on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY)’s Praluent sales. “Our ability to discover and deliver new medicines that benefit patients depends on...

Following a stay granted to allow Regeneron Pharmaceuticals Inc (NASDAQ: REGN)'s PCSK9 franchise Praluent to stay in the market, Credit Suisse said the development is a mild positive for the company. The firm said the company's shares would trade up 2–4 percent based on the headline news,...

After the close on Monday, Amgen, Inc. (NASDAQ: AMGN) announced that the U.S. District Court of Delaware had denied the motion by Sanofi SA (ADR) (NYSE: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to stay the injunction pending the appeal of the ongoing PCSK9 litigation in the Court of...

Despite the District Court’s ruling in favor of Amgen, Inc. (NASDAQ: AMGN) over cholesterol drug Praluent, Leerink believes the patent dispute with Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) is far from over given the possibility of appeal by these firms and...

Following the district court ruling in favor of Amgen, Inc. (NASDAQ: AMGN), Jefferies said in a note on Thursday that the odds of an appeal by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) were low. Analyst Biren Amin noted that the District Court of Delaware...

Following the impressive phase II ORION-1 results for the RNAi drug, inclisiran (a PCSK9 inhibitor for hypercholesterolemia), inclisiran's “expeditious” movement into phase III trials, the injunction granted against Praluent (another PCSK9 inhibitor) Thursday and with PCSK9...

After a strong third quarter with a 7-percent revenue increase, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) justifies a Buy rating from Argus analysts with a $450 target. Analysts also increased Regeneron's 2016 EPS estimate from $11 to $11.58 after the company's GAAP EPS rose 25 percent. Although...

Bernstein has initiated coverage of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) with an Outperform rating and $400 price target, citing a "good entry point for one of stronger growers in biotech." "Regeneron is a growth-phase biopharma with one large successful first product (Eylea) and two...